LCM
KPTI icon

Landscape Capital Management’s Karyopharm Therapeutics KPTI Stock Holding History

Landscape Capital Management’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-2,577
Closed -$512K – 702
2015
Q4 		$512K Buy
+2,577
New +$558K 0.06% 463

Other funds holding KPTI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Landscape Capital Management's KPTI Position: Q1 2016 in Review

Landscape Capital Management sold out of Karyopharm Therapeutics (KPTI) in Q1 2016, closing a stake of 2,577 shares — an estimated $512K sold.

Landscape Capital Management first reported a position in KPTI in Q4 2015 and held it in 1 quarter. The position peaked at $512K in Q4 2015. 77 funds tracked by Wall St. Rank hold KPTI as of Q1 2016.

  • Landscape Capital Management reported no remaining Karyopharm Therapeutics position as of Q1 2016 after selling out during the quarter.
  • Landscape Capital Management sold 2,577 Karyopharm Therapeutics shares in Q1 2016, an estimated $512K.
  • Landscape Capital Management first reported a position in Karyopharm Therapeutics in Q4 2015 and held it in 1 quarter.
  • Landscape Capital Management's Karyopharm Therapeutics position peaked at $512K in Q4 2015.
  • 77 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2016.

Based on Landscape Capital Management's 13F filing for Q1 2016, filed 11 May 2016.